NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis

Company Overview

NewAmsterdam Pharma, Inc. is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation. These investigational compounds are designed to improve glycemic control, support weight management and reduce cardiometabolic risk factors. NewAmsterdam Pharma’s programs emphasize oral delivery formats and aim to provide differentiated safety and efficacy profiles compared with existing therapies.

Headquartered in the United States, NewAmsterdam Pharma leverages a network of research collaborations with academic institutions and industry partners to accelerate its discovery and development activities. The company’s strategic alliances support advancement of its clinical candidates through regulatory milestones and position it to pursue global development and commercialization opportunities for patients with metabolic disorders.

Key Stats

• Today's Range: $23.59 to $24.78
• 50-Day Range: $20.92 to $27.00
• 52-Week Range: $14.06 to $27.35
• Volume: 530,046 shs
• Average Volume: 976,589 shs
• Market Capitalization: $2.76 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $41.55
• Consensus Rating: Moderate Buy

NewAmsterdam Pharma Stock Analysis - MarketRank™

NewAmsterdam Pharma scored higher than 64% of companies evaluated by MarketBeat, and ranked 353rd out of 960 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

NewAmsterdam Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

NewAmsterdam Pharma has a consensus price target of $41.55, representing about 69.4% upside from its current price of $24.52.

Amount of Analyst Coverage

NewAmsterdam Pharma has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for NewAmsterdam Pharma are expected to decrease in the coming year, from ($1.75) to ($1.79) per share.

Price to Book Value per Share Ratio

NewAmsterdam Pharma has a P/B Ratio of 2.99. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.26% of the float of NewAmsterdam Pharma has been sold short.

Short Interest Ratio / Days to Cover

NewAmsterdam Pharma has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in NewAmsterdam Pharma has recently increased by 2.32%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NewAmsterdam Pharma does not currently pay a dividend.

Dividend Growth

NewAmsterdam Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

10.26% of the float of NewAmsterdam Pharma has been sold short.

Short Interest Ratio / Days to Cover

NewAmsterdam Pharma has a short interest ratio ("days to cover") of 8.2.

Change versus previous month

Short interest in NewAmsterdam Pharma has recently increased by 2.32%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.04

News Sentiment

NewAmsterdam Pharma has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for NewAmsterdam Pharma this week, compared to 7 articles on an average week.

Search Interest

Only 3 people have searched for NAMS on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added NewAmsterdam Pharma to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 5.0 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, NewAmsterdam Pharma insiders have sold 3,395.41% more of their company's stock than they have bought. Specifically, they have bought $279,621.00 in company stock and sold $9,773,906.00 in company stock.

Percentage Held by Insiders

20.84% of the stock of NewAmsterdam Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

NAMS Stock Analysis - Frequently Asked Questions

How have NAMS shares performed this year?

NewAmsterdam Pharma's stock was trading at $25.70 at the beginning of the year. Since then, NAMS shares have decreased by 4.6% and is now trading at $24.52.

How were NewAmsterdam Pharma's earnings last quarter?

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) released its earnings results on Wednesday, August, 6th. The company reported ($0.15) earnings per share for the quarter, topping the consensus estimate of ($0.52) by $0.37. The firm earned $19.15 million during the quarter, compared to analysts' expectations of $1.44 million. NewAmsterdam Pharma had a negative net margin of 259.07% and a negative trailing twelve-month return on equity of 27.27%.

Who are NewAmsterdam Pharma's major shareholders?

NewAmsterdam Pharma's top institutional shareholders include Frazier Life Sciences Management L.P. (14.79%), Adage Capital Partners GP L.L.C. (2.68%), Jennison Associates LLC (2.62%) and Alliancebernstein L.P. (2.08%). Insiders that own company stock include Nap BV Forgrowth, James N Topper, Michael H Davidson, Johannes Jacob Piete Kastelein, Douglas F Kling, Louis G Lange, Louise Frederika Kooij and Juliette Berangere Audet.
View institutional ownership trends.

How do I buy shares of NewAmsterdam Pharma?

Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of NewAmsterdam Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NewAmsterdam Pharma investors own include Nextera Energy Partners (NEP), Enterprise Products Partners (EPD), Blue Owl Capital (OBDC), Pimco Corporate & Income Opportunity Fund (PTY), PayPal (PYPL) and Ventyx Biosciences (VTYX).

Company Calendar

• Last Earnings: 8/06/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 11/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:NAMS
• CIK: 1936258
• Web: www.newamsterdampharma.com
• Phone: 352062971
• Fax: N/A
• Employees: 4
• Year Founded: N/A

Price Target and Rating

• Average Price Target for NewAmsterdam Pharma: $41.55
• High Price Target: $52.00
• Low Price Target: $27.00
• Potential Upside/Downside: +69.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.62)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$241.60 million
• Net Margins: -259.07%
• Pretax Margin: -258.91%
• Return on Equity: -27.27%
• Return on Assets: -25.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 21.08
• Quick Ratio: 21.08

Sales & Book Value

• Annual Sales: $45.56 million
• Price / Sales: 60.62
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $8.20 per share
• Price / Book: 2.99

Miscellaneous

• Outstanding Shares: 112,630,000
• Free Float: 89,156,000
• Market Cap: $2.76 billion
• Optionable: Optionable
• Beta: -0.01